COMMUNIQUÉS West-GlobeNewswire

XORTX Therapeutics Announces Appointment of Allan Williams and Paul Van Damme
29/01/2018
CALGARY, Alberta, Jan. 29, 2018 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (" XORTX " or the “ Company ”) (CSE:XRX), a BioPharmaceutical company focused on developing innovative therapies to treat progressive kidney [...]
Canadian Drug Expert Committee Grants Positive Recommendation for Reimbursement of Galafold™ (migalastat) for Fabry Disease in Canada
29/01/2018
CRANBURY, N.J., Jan. 29, 2018 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD ) announced that the Common Drug Review (CDR) has posted the Canadian Drug Expert Committee (CDEC)’s positive recommendation of [...]
Alder BioPharmaceuticals, Inc. Announces Offering of $200 Million of Convertible Senior Notes Due 2025
29/01/2018
BOTHELL, Wash., Jan. 29, 2018 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ: ALDR ), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of migraine, announced [...]
Faron Pharmaceuticals Oy: FDA grants Fast Track Designation to Faron for Traumakine®
29/01/2018
Faron Pharmaceuticals Ltd ("Faron" or the "Company") FDA grants Fast Track Designation to Faron for Traumakine ® Faron's wholly-owned product for Acute Respiratory Distress Syndrome on track for Phase III data in H1 [...]
Rhizen Pharmaceuticals S.A. announces clinical data presentations for Tenalisib (RP6530) in R/R T-cell lymphoma at the upcoming 10th Annual T-Cell Lymphoma Forum in La Jolla, CA, USA
29/01/2018
La Chaux-de-Fonds, Switzerland, Jan. 29, 2018 (GLOBE NEWSWIRE) -- Rhizen Pharmaceuticals S.A., today announced that updated clinical data for Tenalisib (RP6530), the company’s highly selective and orally active dual [...]
Microbix Featured at Cantech Investment Conference
29/01/2018
TORONTO, Jan. 29, 2018 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (TSX: MBX ) (Microbix ® ), an innovator of biological products and technologies, announces its participation as a panelist and exhibitor at the Cantech [...]
Protalix BioTherapeutics to Participate in the 14th Annual WORLDSymposium™ 2018
29/01/2018
CARMIEL, Israel, Jan. 29, 2018 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE MKT:PLX) (TASE: PLX ), announced today that the Company will participate in the 14 th Annual WORLD Symposium™ 2018 taking place [...]
Melinta Therapeutics Launches Antibiotic Baxdela™ (delafloxacin) in the United States
29/01/2018
– Approved for adult patients with acute bacterial skin and skin structure infections (ABSSSI) – – Provides coverage of gram-positive and gram-negative pathogens; only FDA-approved fluoroquinolone for methicillin- [...]
Athersys CEO to Speak at the 2018 Brain Health Summit
29/01/2018
CLEVELAND, Ohio, Jan. 29, 2018 (GLOBE NEWSWIRE) -- Athersys, Inc. (NASDAQ: ATHX ) announced today that Gil Van Bokkelen, Chairman and CEO, will be a speaker and panelist at the 2018 Brain Health Summit organized by the [...]
Genetic Technologies Limited: Quarterly Activities Report and Appendix 4C of the ASX Listing Rules for the quarter ended 31 December 2017
29/01/2018
HIGHLIGHTS Completed a three month promotional campaign leading up to and throughout October Breast Cancer Awareness Month Ohio State University: patient recruitment for the collaborative clinical research study [...]
SuperSonic Imagine to Present Aixplorer® Ultimate at the Arab Health Congress
29/01/2018
AIX-EN-PROVENCE, France, Jan. 29, 2018 (GLOBE NEWSWIRE) -- SuperSonic Imagine (Euronext: SSI) (FR0010526814, eligible savings plan in shares-SME), an ultrasound medical imaging company, presents Aixplorer ® Ultimate, [...]
Correction to company release dated January 26, 2018 - Conversion of FIT Biotech Oy's Convertible Capital Notes into shares - number of shares
29/01/2018
FIT Biotech Oy Company release January 29, 2018 at 11:35 AM EET Correction to company release dated January 26, 2018 - Conversion of FIT Biotech Oy's Convertible Capital Notes into shares - number of shares Due to the [...]
Christoffer Lorenzen appointed member of the Executive Board of Chr. Hansen Holding A/S
29/01/2018
Company Announcement No. 4/2018 http://prlibrary-eu.nasdaq.com/Resource/Download/18843394-b4f7-4201-8d23-a23ed4168976
CORRECTION:Sanofi va acquérir Ablynx pour 3,9 milliards d'euros
29/01/2018
Il sagit dune correction du communiqué 08:19 29.01.2018 CET. Explication de la modification: Le nom d'Ablynx était mal orthographié dans le 11ème paragraphe. Communiqué de Presse Source: Sanofi (EURONEXT: SAN) (NYSE: [...]
Proposals of the Shareholders' Nomination Board of Terveystalo Plc to the Annual General Meeting 2018
29/01/2018
Terveystalo Plc Stock Exchange Release 29 January 2018 at 10:00 EET The Shareholders' Nomination Board of Terveystalo has submitted its proposal on the Board of Directors to the Annual General Meeting 2018. Proposal on [...]
Reminder Invitation webcast Year-end report 2017
29/01/2018
Press release 2018-01-29 Reminder: C-RAD Web Presentation Year-end Report 2017 Presentation of the report for the fiscal year 2017: Date: Thursday January 31, 2018 / kl. 11:00 Venue: Online Presentation Topic: C-RAD [...]
CellaVision AB presents the year-end bulletin for 2017 on February 9 at 11:00 CET
29/01/2018
The information was submitted to the public on January 29, 2018 at 8:20 CET CellaVision will publish the year-end bulletin for 2017 on February 9, 2018 at 08:20 CET. The report will be available at www.cellavision.com [...]
SANOFI TO ACQUIRE ABLYNX FOR €3.9 BILLION
29/01/2018
Regulated information - inside information Strengthens Sanofi's R&D strategy with innovative Nanobody ® technology platform Expands growing rare blood disorders franchise with Ablynx's late-stage investigational [...]
Sanofi to acquire Ablynx for €3.9 Billion
29/01/2018
Press Release Source: Sanofi (EURONEXT: SAN) (NYSE: SNY) Sanofi to acquire Ablynx for €3.9 Billion Strengthens Sanofi's R&D strategy with innovative Nanobody ® technology platform Expands growing rare blood [...]

Pages